Novartis Takeover Bid for MorphoSys Tops Minimum Acceptance Threshold

Novartis' (NOVN.SW) takeover offer surpassed the 65% minimum threshold as it was accepted by 79.6% of MorphoSys shareholders. Settlement of the shares tendered during the initial acceptance period, wh

MT Newswires18:04

Novartis Meets All Tender Offer Conditions to Acquire MorphoSys for EUR 68 Per Share in Cash

Novartis Meets All Tender Offer Conditions to Acquire MorphoSys for EUR 68 Per Share in Cash

Dow Jones17:29

Voyager Therapeutics up 8% Following Quarterly Beats

Seeking AlphaMay 14 05:41

European Buy-rated Stocks That Trade Cheaply Vs. Their U.S. Peers - UBS

Seeking AlphaMay 11 22:00

MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'

MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo).TAMARACK is being conducted in previously treated patients with metastatic

BenzingaMay 11 03:08

Novartis Gets FDA Breakthrough Designation For Scemblix

Novartis Gets FDA Breakthrough Designation For Scemblix

BenzingaMay 10 21:03